Neboglamine

Drug Profile

Neboglamine

Alternative Names: CR-2249; Nebostinel; XY 2401

Latest Information Update: 08 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rottapharm
  • Developer Rottapharm; Rottapharm Madaus; Xytis
  • Class Neuroprotectants; Nootropics; Pentanoic acids; Small molecules
  • Mechanism of Action Glycine NMDA-associated agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine abuse; Schizophrenia
  • Discontinued Alzheimer's disease; Major depressive disorder

Most Recent Events

  • 08 Jun 2015 Phase-II development for schizophrenia (negative, cognitive and mood symptoms) and drug abuse (cocaine abuse) is ongoing in Italy and USA, respectively
  • 08 Nov 2014 Phase-II development is ongoing in the US and Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top